Instrument Inactif

Communiqués Anacor Pharmaceuticals Inc

Actions

US0324201013

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

2016	Anacor Pharmaceuticals : Pfizer rachète Anacor Pharma pour 5,2 milliards de dollars	RE
2016	AbbVie : La chute des biotechs pourrait favoriser les fusions-acquisitions	RE

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Ryan & Maniskas, LLP : Announces Investigation of Anacor Pharmaceuticals, Inc.	18/05/16	PR
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	17/05/16	BU
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information	16/05/16	BU
Anacor Pharmaceuticals : Reports First Quarter 2016 Financial Results	10/05/16	BU
Anacor Pharmaceuticals : to Report First Quarter 2016 Financial Results on May 10, 2016	09/05/16	PU
Anacor Pharmaceuticals : to Report First Quarter 2016 Financial Results on May 10, 2016	04/05/16	BU
Anacor Pharmaceuticals : to Present at the Deutsche Bank 41st Annual Healthcare Conference	02/05/16	BU
Anacor Pharmaceuticals : Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023	01/04/16	BU
Anacor Pharmaceuticals : Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023	30/03/16	BU
Anacor Pharmaceuticals : Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis	22/03/16	BU
Anacor Pharmaceuticals : to Present at the Cowen and Company 36th Annual Health Care Conference	03/03/16	BU
Anacor Pharmaceuticals : Reports 2015 Fourth Quarter and Year-End Financial Results	29/02/16	BU
Anacor Pharmaceuticals : Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at the 74th Annual Meeting of the American Academy of Dermatology	23/02/16	BU
Anacor Pharmaceuticals : Announces 2015 Fourth Quarter and Year-End Financial Results Conference Call and Webcast	22/02/16	BU
Anacor Pharmaceuticals : to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference	08/01/16	BU
Anacor Pharmaceuticals : Submits New Drug Application to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis	07/01/16	BU
Anacor Pharmaceuticals : to Present at the Jefferies Autumn 2015 Global Healthcare Conference	12/11/15	BU
Anacor Pharmaceuticals : Reports Third Quarter 2015 Financial Results	03/11/15	BU
Anacor Pharmaceuticals : Announces Top-Line Results From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis	29/10/15	BU
Anacor Pharmaceuticals : to Report Third Quarter 2015 Financial Results on November 3, 2015	28/10/15	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Anacor Pharmaceuticals Inc

Actions

US0324201013

Communiqués

Filtres